Cases & Deals

Boehringer Ingelheim and Epizyme enter into global collaboration to develop novel epigenetic oncology therapies

Clients Boehringer Ingelheim GmbH

Jones Day represents Boehringer Ingelheim GmbH and Epizyme, Inc. in the establishment of a global patent portfolio related to small molecules to target enzymes within the helicase and histone acetyltransferase ("HAT") families.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.